NORAH OWINO: Open Payments
NPI 1467032706 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,175 in 138 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $2,582 · 2025 $3,175
Food & beverage: $3,175
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 48 | $868 |
| AstraZeneca Pharmaceuticals LP | 10 | $576 |
| GENZYME CORPORATION | 11 | $335 |
| Verona Pharma, Inc. | 18 | $334 |
| Inspire Medical Systems, Inc. | 14 | $293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $228 |
| Regeneron Healthcare Solutions, Inc. | 10 | $177 |
| Actelion Pharmaceuticals US, Inc. | 5 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Insmed, Inc. | 2 | $49 |
Products named: NUCALA, DUPIXENT, Ohtuvayre, TRELEGY ELLIPTA, INSPIRE, AIRSUPRA, BREZTRI, ARALAST.
Industry payments across TX — which companies pay providers there.
